Huapai Bio Group Completes First Round of Financing with Investment from Guoxin Hengsheng, Prominent Industrial Investor, and Jinmu Capital; Keycheng Capital Acts as Exclusive Financial Advisor

VCBeat has learned that Huapai Biotechnology (Group) Co., Ltd. (“Huapai Bio”) recently completed its first round of financing. The investment was participated in by the Chuanyu Guanghong Fund under Guoxin Hongsheng, a well-known industrial investor, and Jinmu Capital, among others. WinX Capital served as the exclusive financial advisor.

Huapai Biotechnology is a group-oriented animal health enterprise with decades of industry experience, specializing in the R&D, production, sales, and technical services of veterinary biological vaccines, antibodies, diagnostic reagents, and veterinary drugs. The Group has successively established five veterinary biological product production bases—namely, the Huapai Group Headquarters, Chongqing Aolong, Chongqing Yongjian, Tengchong Huayu, and Zhuji Gaoling—as well as the Chengdu Jinghua Pharmaceutical production base. Currently, it operates 22 veterinary biological product production lines and 19 veterinary drug production lines. These include China’s first nucleic acid vaccine production line to pass Good Manufacturing Practice (GMP) inspection and acceptance, along with three cell suspension culture production lines. The company offers over 40 veterinary vaccine products and more than 270 veterinary drug products, with its production scale and capacity for biological products and veterinary drugs ranking among the industry leaders.

Huapai Biotechnology Group is the only enterprise in the animal health industry to comprehensively cover five major mandatory vaccination programs: foot-and-mouth disease, echinococcosis, peste des petits ruminants, brucellosis, and avian influenza. Centered on these five mandatory vaccines, the company has established a multi-dimensional presence in the field of veterinary biological products, with comprehensive coverage of market-driven animals including pigs, poultry, cattle, sheep, and rabbits, boasting the most extensive product portfolio in the industry. Additionally, it has proactively expanded into the pet care sector, building a robust pipeline of reserve products.

Currently, Huapai Biotechnology Group, with its comprehensive portfolio of biological vaccines, animal health pharmaceuticals, and all-encompassing technical services, effectively addresses the critical pain points and challenges faced by numerous large-scale livestock farming enterprises. It has become the preferred brand for disease prevention and control among major farming groups. The company contributes to strengthening China’s animal epidemic prevention system, the control of zoonotic diseases, and the establishment of a food safety system for animal-derived products.

WinX CapitalStatement: Animal diseases are closely linked to national welfare and people's livelihoods, presenting broad prospects for the animal health market. Huapai Biotechnology Group is a rare, mature investment target in the animal health sector, possessing significant growth potential. The company boasts a comprehensive product portfolio, strong R&D capabilities, and a robust sales network, demonstrating exceptional overall strength. We wish Huapai Biotechnology Group accelerated development and great success as it leverages its 30 years of profound expertise with the support of capital and diverse resources.

The Chuanyu Guanghong Fund was jointly established by Guoxin Hongsheng and Sichuan Guang'an Investment Group. It focuses on investing in key sub-sectors of the pharmaceutical and healthcare industry, including active pharmaceutical ingredients (APIs), chemical formulations, traditional Chinese medicine preparations, biological products, medical devices, raw materials for medical aesthetics, and medical services. The fund is fully committed to empowering the high-quality development of the pharmaceutical and healthcare industries with competitive advantages in the Chengdu-Chongqing Twin City Economic Circle.